Introducing Orynotides

Macrocyclic Peptide Therapeutics

Revolutionary therapeutics inspired by naturally occurring biomolecules

Orynotides are small cyclic peptides, biomolecules that offer the potential to safely treat autoimmune and chronic inflammatory diseases, drug resistant infections, and cancer. Orynotides have immunomodulatory properties shown to be effective in preclinical models of human disease. Orynotide ORTD-1 is now in clinical trials for rheumatoid arthritis and COVID-19.

Unique Properties of Orynotides

Orynotides are engineered analogs of theta-defensins, macrocyclic peptide molecules that occur naturally in some species of primates, but not humans. Like naturally occurring theta defensins, Orynotides are stable, non-toxic with no modification, and non-immunogenic.

Engineering Novel Therapeutics

Oryn Therapeutics pioneered research into the therapeutic properties of theta defensins. Company scientists have employed a novel retro-evolutionary approach that has given rise to novel immunoregulatory therapeutics effective in preclinical models of infectious, inflammatory, autoimmune diseases as well as cancer.

Theta Defensins: The Bioinspired Template for Orynotides

Rhesus theta defensin 1 (RTD-1) molecular ribbon diagram showing backbone (blue) cyclized peptide stabilized by 3 disulfide bonds (yellow).

ORTD-1 is just the beginning.

Learn More About Our Pipeline

Application of Biological Mechanisms

The therapeutic properties of Orynotides are mediated by immune modulation of host responses to infection, dysregulated inflammation, and cancer. Unlike monoclonal antibody biologics that completely block the activity of specific molecules, Orynotides inhibit disease processes in a rheostat-like fashion that replicates biological regulation of these pathways. Thus, in preclinical models, Orynotides act as homeostatic agents that enhance the host response to disease, and do so without significant adverse side effects.